Genitourinary Cancer News

Patients with cancer appeared at increased risk for arterial thromboembolism and mortality within 1 year of cancer diagnosis compared with the general population, according to an epidemiological analysis published in JACC: CardioOncology.

Patients with cancer may be at high risk for venous thromboembolism and arterial thromboembolic events while undergoing treatment with immune checkpoint inhibitors, according to study results published in Blood.

During the past 2 decades, addressing the psychosocial needs of patients with cancer has become recognized as a crucial component of treatment, but experts said work remains to fully integrate mental health into routine cancer care.

The FDA granted priority review to two supplemental biologics license applications for enfortumab vedotin-ejfv in the treatment of locally advanced or metastatic urothelial cancer.

Neeraj Agarwal, MD, has been appointed senior director of clinical research innovation at Huntsman Cancer Institute at University of Utah.

The FDA today granted accelerated approval to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

A personalized genomic vaccine administered after standard-of-care adjuvant therapy appeared safe and induced immunogenicity among patients with different cancers at a high risk for recurrence, according to results of a phase 1 trial.

Going through cancer during transitional adolescent and young adult years can present additional social, financial and mental health challenges that add to the stressors of diagnosis and treatment.

Adjuvant pembrolizumab prolonged DFS compared with placebo for patients with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

The FDA cleared an investigational new drug application for the combination of AFM24 and SNK-01 in patients with solid tumors that express epidermal growth factor receptor, according to a joint press release from each agent’s manufacturer.